Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 3/4)
유사 논문P · Population 대상 환자/모집단
332 patients of which 211 (63.
I · Intervention 중재 / 시술
EGFR mutation testing were included
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Mutational frequencies remain similar, with the highest frequencies being for exon 19 and 21 mutations. [SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-14839-w.
[BACKGROUND] This study aims to update the mutational status of EGFR in non-small cell carcinoma (NSCLC), to analyze the spectrum of mutations found, and describe rare mutations in the Lebanese popula
APA
Kourie HR, Farhat C, et al. (2026). Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.. BMC cancer, 26(1). https://doi.org/10.1186/s12885-025-14839-w
MLA
Kourie HR, et al.. "Updated incidence of EGFR mutation in Middle Eastern patients with non-small cell lung cancer: a 7-year study in a Lebanese institution.." BMC cancer, vol. 26, no. 1, 2026.
PMID
41656191 ↗
Abstract 한글 요약
[BACKGROUND] This study aims to update the mutational status of EGFR in non-small cell carcinoma (NSCLC), to analyze the spectrum of mutations found, and describe rare mutations in the Lebanese population.
[METHODS] In this retrospective study, patients diagnosed with NSCLC between 2016 and 2023 who underwent EGFR mutation testing were included. EGFR mutations from 2016 to 2019 were analyzed using real-time PCR on the Rotor-Gene Q platform, while those from 2019 to 2023 were analyzed using real-time PCR with the Idylla system.
[RESULTS] 332 patients of which 211 (63.3%) men and 121 (36.7%) women were included. Mean age was 65.7 years. Adenocarcinoma was the main histological subtype. Additionally, 16.3% of patients had an EGFR mutation: 50% had a deletion on exon 19, 37% an L858R mutation, 4% a G719/C/S mutation, 4% a T790M mutation alone, 2% an L861Q mutation alone, and 2% a S768I mutation alone. A statistically significant difference ( < 0.0285) was found between the positivity rates of the two EGFR mutation detection techniques, favoring the Idylla technique.
[CONCLUSION] We confirmed the variation in the incidence of mutated NSCLC between Lebanon and the region. Mutational frequencies remain similar, with the highest frequencies being for exon 19 and 21 mutations.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-14839-w.
[METHODS] In this retrospective study, patients diagnosed with NSCLC between 2016 and 2023 who underwent EGFR mutation testing were included. EGFR mutations from 2016 to 2019 were analyzed using real-time PCR on the Rotor-Gene Q platform, while those from 2019 to 2023 were analyzed using real-time PCR with the Idylla system.
[RESULTS] 332 patients of which 211 (63.3%) men and 121 (36.7%) women were included. Mean age was 65.7 years. Adenocarcinoma was the main histological subtype. Additionally, 16.3% of patients had an EGFR mutation: 50% had a deletion on exon 19, 37% an L858R mutation, 4% a G719/C/S mutation, 4% a T790M mutation alone, 2% an L861Q mutation alone, and 2% a S768I mutation alone. A statistically significant difference ( < 0.0285) was found between the positivity rates of the two EGFR mutation detection techniques, favoring the Idylla technique.
[CONCLUSION] We confirmed the variation in the incidence of mutated NSCLC between Lebanon and the region. Mutational frequencies remain similar, with the highest frequencies being for exon 19 and 21 mutations.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12885-025-14839-w.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Generational trends in reproductive factors among women in the US: implications for breast cancer incidence.
- Acquired L858R mutation following -TKI resistance in lung adenocarcinoma: a case report.
- Clinical Characteristics and Prognostic Prediction of Secondary Solid Malignancies in Patients With Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
- Environmental endocrine disruptors and endometrial cancer: a systematic review of epidemiological studies.